An Open-label Study of the Effect of First-line Herceptin Alone or in Combination With a Taxane on Tumor Response and Disease Progression in Patients With Metastatic Breast Cancer Who Relapsed After Receiving Adjuvant Herceptin for HER2-positive Early Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2014
At a glance
- Drugs Trastuzumab (Primary) ; Docetaxel; Paclitaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms RHEA
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 16 Oct 2012 Planned number of patients changed from 40 to 80.
- 18 Sep 2012 Planned end date changed from 1 Jul 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.